A Randomized, Open-Label Study Of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) To Evaluate Hematologic Response Rate In Anemic Cancer Patients Receiving Chemotherapy
Chemotherapy related anemia occurs in a majority of cancer patients and can cause impaired
treatment outcomes, increased treatment-related complications and altered quality of life.
Epoetin alfa administered on a weekly dosing schedule of 40,000 Units subcutaneously ([SC],
under the skin) with dose adjustments based on hematologic response produces significant
improvement in hemoglobin levels, decreased transfusion frequency and improved quality of
life. It is unknown if the recently developed agent, darbepoetin alfa, administered on an
every other week fixed dose will produce similar improvements in hematologic and quality of
life outcomes. Thus, further randomization studies are warranted utilizing once weekly
dosing (QW) of Epoetin alfa compared to once every other week (Q2W) darbepoetin alfa.
Patients will receive study medications for up to 16 weeks.Safety & efficacy evaluations
will be performed at specified intervals throughout the study.The study hypothesis is that
the Week 5 hemoglobin response rate in the Epoetin alfa group is better than that in the
Darbepoetin alfa group. The starting dose for study drug is either Epoetin alfa (PROCRIT)
40,000 Units SC QW or Darbepoetin alfa (ARANESP) 200 mcg SC Q2W. Doses may be adjusted
depending on the patient's hemoglobin levels up a maximum of 60,000 IU SC QW Epoetin alfa or
300 mcg SC Q2W Darbepoetin alfa.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary efficacy endpoint will evaluate the proportion of patients achieving >1 g/dL hemoglobin increase by week 5.
Ortho Biotech Products, L.P. Clinical Trial
Ortho Biotech Products, L.P.
United States: Institutional Review Board